Kaitlin S. Earley, C.N.M. Nurse Practitioner - Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 895 Dettloff Dr, Arcadia, WI 54612 Phone: 608-785-0940 |
Sherri L Bohlinger, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 625 W Main St, Arcadia, WI 54612 Phone: 608-323-3210 |
Mary B Klonecki, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 625 W Main St, Arcadia, WI 54612 Phone: 608-323-3210 |
Marilyn Rose Motszko, APRN Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 464 S Saint Joseph Ave, Arcadia, WI 54612 Phone: 608-323-3341 |
Connie M Hoppe, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 209 N 3rd St, Arcadia, WI 54612 Phone: 608-782-7300 |
News Archive
A new collaboration between the Department of Energy's Pacific Northwest National Laboratory and the Air Force's 59th Medical Wing hopes to improve on drug tests for illicit drug use and abuse. Not only are the researchers looking for a better indicator of current or past use, but they'd like to be able to identify people prone to abusing drugs in the first place.
Scientists at the University of Washington (UW) Department of Genome Sciences have identified several sporadic or "de novo" genetic mutations in children with autism spectrum disorder. The researchers applied leading edge molecular biology techniques and massively parallel sequencing to simultaneously examine all of the protein coding portions of the genome, collectively called the exome.
A research paper in the latest issue of Medical Journal of Australia has provided the first insight into the prevalence and patterns of multimorbidity in Australia. About three in 10 people who saw a GP in 2005, and one in four Australians have multimorbidity (two or more types of chronic conditions).
A noninvasive brainwave mirroring technology significantly reduced symptoms of post-traumatic stress in military personnel in a pilot study conducted at Wake Forest Baptist Medical Center.
iCo Therapeutics Inc. - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.
› Verified 2 days ago